Marianne P. Allen

Array ( [id] => 19018962 [patent_doc_number] => 20240075133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCTION OF IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 18/335656 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111282 [patent_doc_number] => 20240123032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRING [patent_app_type] => utility [patent_app_number] => 18/327544 [patent_app_country] => US [patent_app_date] => 2023-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18327544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955191 [patent_doc_number] => 20240043518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => HEAVY CHAIN ONLY ANTIBODIES TO PDGF [patent_app_type] => utility [patent_app_number] => 18/322927 [patent_app_country] => US [patent_app_date] => 2023-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861927 [patent_doc_number] => 20230416362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTI-TIGIT ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/318776 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861971 [patent_doc_number] => 20230416407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => FGF21 MIMETIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/197190 [patent_app_country] => US [patent_app_date] => 2023-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18197190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597303 [patent_doc_number] => 20230272098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A [patent_app_type] => utility [patent_app_number] => 18/316811 [patent_app_country] => US [patent_app_date] => 2023-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 174752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -76 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18316811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752506 [patent_doc_number] => 20230355763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => NANOPARTICLE VACCINES AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF ATHEROSCLEROSIS USING PEPTIDE 210 AS AN ANTIGEN [patent_app_type] => utility [patent_app_number] => 18/312194 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692639 [patent_doc_number] => 20230322961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => ANTI-CD28 X ANTI-PSMA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/311771 [patent_app_country] => US [patent_app_date] => 2023-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786098 [patent_doc_number] => 20230374090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/311082 [patent_app_country] => US [patent_app_date] => 2023-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387994 [patent_doc_number] => 20240277864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/307729 [patent_app_country] => US [patent_app_date] => 2023-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18307729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227218 [patent_doc_number] => 12415861 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Anti C-MET antibodies [patent_app_type] => utility [patent_app_number] => 18/304598 [patent_app_country] => US [patent_app_date] => 2023-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 22503 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 509 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806798 [patent_doc_number] => 20230381130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => ANTIBODY SCAFFOLD STRUCTURE [patent_app_type] => utility [patent_app_number] => 18/300198 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537523 [patent_doc_number] => 20230242620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 18/299871 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902760 [patent_doc_number] => 20240018245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/295539 [patent_app_country] => US [patent_app_date] => 2023-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18295539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20505910 [patent_doc_number] => 12540177 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => True human antibody specific for interleukin 1 alpha [patent_app_type] => utility [patent_app_number] => 18/295201 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 0 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18295201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707674 [patent_doc_number] => 20230330254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/182323 [patent_app_country] => US [patent_app_date] => 2023-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18182323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770907 [patent_doc_number] => 20230365711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => ANTI-CEA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/180977 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18180977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550806 [patent_doc_number] => 20230248806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => Liquid Formulation of a VEGF Antagonist [patent_app_type] => utility [patent_app_number] => 18/173549 [patent_app_country] => US [patent_app_date] => 2023-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18173549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116053 [patent_doc_number] => 12365743 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Anti-CD28 x anti-PSMA antibodies [patent_app_type] => utility [patent_app_number] => 18/172987 [patent_app_country] => US [patent_app_date] => 2023-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 173 [patent_figures_cnt] => 189 [patent_no_of_words] => 96191 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18172987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20445211 [patent_doc_number] => 20260001928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-01 [patent_title] => CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 18/839784 [patent_app_country] => US [patent_app_date] => 2023-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18839784 [rel_patent_id] =>[rel_patent_doc_number] =>)